|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Pfizer |
Washington University |
$25M |
Washington University and Pfizer researchers will identify, design and execute projects focused on immuno-inflammatory disorders such as arthritis, asthma and diabetes. |
|
Forest Laboratories |
Novexel's |
$109.6 million |
Forest gains development rights to Novexel's intravenous beta lactamase inhibitor, NXL 104, in combination with Forest's ceftaroline. |
|
Teva |
CoGenesys |
$400 million |
Teva says the buyout will give it a better position to compete in the fledgling biogeneric field. |